{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444003955
| ImageFile = Glibornuride.svg
| ImageSize = 250
| IUPACName = 1-(3-hydroxy-4,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl)-3-(4-methylphenyl)sulfonylurea
| OtherNames =

| Section1 = {{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = VP83E7434R
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=26944-48-9
| PubChem=33649
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB08962
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02427
| SMILES=CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2C3CCC(C2O)(C3(C)C)C
| InChI = 1/C18H26N2O4S/c1-11-5-7-12(8-6-11)25(23,24)20-16(22)19-14-13-9-10-18(4,15(14)21)17(13,2)3/h5-8,13-15,21H,9-10H2,1-4H3,(H2,19,20,22)/t13-,14+,15+,18+/m1/s1
| InChIKey = RMTYNAPTNBJHQI-LLDVTBCEBZ
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C18H26N2O4S/c1-11-5-7-12(8-6-11)25(23,24)20-16(22)19-14-13-9-10-18(4,15(14)21)17(13,2)3/h5-8,13-15,21H,9-10H2,1-4H3,(H2,19,20,22)/t13-,14+,15+,18+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = RMTYNAPTNBJHQI-LLDVTBCESA-N
| RTECS = 
| MeSHName = C073323
| EINECS = 248-124-6
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 16735831
  }}

| Section2 = {{Chembox Properties
| Formula = C<sub>18</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>S
| MolarMass = 366.48 g/mol
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}

| Section6 = {{Chembox Pharmacology
| ATCCode_prefix = A10
| ATCCode_suffix = BB04
 }}

| Section7 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
}}

'''Glibornuride''' ([[International Nonproprietary Name|INN]]) is an [[anti-diabetic drug]] from the group of [[sulfonylurea]]s.<ref>{{cite journal |vauthors=Haupt E, Köberich W, Beyer J, Schöffling K |title=Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects |journal=Diabetologia |volume=7 |issue=6 |pages=449–54 |date=December 1971 |pmid=5004178 |doi=10.1007/bf01212061}}</ref> It is manufactured by [[Meda AB|MEDA Pharma]] and sold in [[Switzerland]] under the brand name '''Glutril'''.<ref>{{cite web|title=Glutril — Drugs.com|url=https://www.drugs.com/international/glutril.html|website=Drugs.com|accessdate=12 July 2016}}</ref>

== Synthesis ==
[[File:Glibornuride synthesis.svg|thumb|center|700px|Glibornuride synthesis:<ref>{{Cite journal|doi=10.1007/BF01151769|title=Arylsulfonylureido- und Arylsulfonylamidoacyl-derivate von Oxy- und Oxo-cycloalkanen als potentielle Antidiabetica|journal=Monatshefte für Chemie |volume=100|issue=6|pages=2133|year=1969|last1=Bretschneider|first1=H.|last2=Hohenlohe-Oehringen|first2=K.|last3=Graßmayr|first3=K.}}</ref> See also: {{US patent|3770761}}; eidem, {{US patent|3654357}} (to Hoffmann-La Roche).]]
Gliburnide is an endo-endo derivative made from camphor-3-carboxamode by borohydride reduction (exo approach), followed by [[Hofmann rearrangement]] to carbamate, followed by displacement with sodium tosylamide.

== References ==
{{Reflist}}

{{Oral hypoglycemics and insulin analogs}}
{{Ion channel modulators}}

[[Category:Potassium channel blockers]]
[[Category:Alcohols]]
[[Category:Sulfonylureas]]

{{gastrointestinal-drug-stub}}